Click "Review Abstract" Links Below to Review Journal Articles
A sensitive and specific test that improves upon traditional means of diagnosing rheumatoid arthritis (RA) .
AVISE MCV detects autoantibodies to mutated citrullinated vimentin (MCV). MCV is a naturally occurring protein isoform that is found within the inflamed synovium of patients with RA, whereas other citrullinated peptide markers use a synthetic antigen composition.
Avise MCV is a useful adjunct to traditional clinical and laboratory methods for diagnosing RA. Several studies have established the clinical performance of anti-MCV in diagnosing RA. The clinical performance of anti-MCV versus anti-CCP across eight peer reviewed studies can be summarized as follows:
* Studies included anti-CCP tests from multiple manufacturers and generations: anti-CCP2 and anti-CCP3.1.
Avise MCV offers a high level of diagnostic accuracy as well as helps to identify patients who are likely to have more severe disease progression . Graphs below illustrate the difference over a five year period in two common clinical parameters of RA patients who are positive versus negative at baseline.
Avise MCV has a unique diagnostic spectrum, meaning that it will be positive even in a certain percentage of patients who are negative for both anti-CCP and RF. The diagram below illustrates the findings from one study where 10% of early RA patients were positive for Avise MCV, but negative for RF and anti-CCP. 
Diagram of Lab Marker Sensitivity
Early diagnosis and appropriate treatment of rheumatoid arthritis are critically important to prevent erosive joint destruction and disability. Anti-MCV testing provides the potential to better detect patients who have RA and identify those likely to experience more severe disease progression.
Avise MCV results are provided on a color graph to facilitate easy interpretation and dialogue with patients. Below is an example of the result report.